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Abstract: Peripheral T-cell lymphomas (PTCLs) comprise a rare and heterogeneous subset of 
non-Hodgkin’s lymphomas (NHLs) that arise from post-thymic T-cells or natural killer (NK)-
cells at nodal or extranodal sites. Worldwide, PTCLs represent approximately 12% of all NHLs 
and the 2008 World Health Organization (WHO) classification includes over 20 biologically and 
clinically distinct T/NK-cell neoplasms that differ significantly in presentation, pathology, and 
response to therapy. Because of the rarity and heterogeneity of these diseases, large clinical trials 
have not been conducted and optimal therapy is not well defined. Most subtypes are treated with 
similar combination chemotherapy regimens as used for aggressive B-cell NHL, but with poorer 
outcomes. New treatment combinations and novel agents are currently being explored for PTCLs 
and this review highlights a number of options that appear promising.
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Introduction
Peripheral T-cell lymphomas (PTCLs) are a subset of non-Hodgkin’s lymphomas 
(NHLs) that arise from lymphocytes at the post-thymic stage of maturation, which 
display T-cell or natural killer (NK)-cell immunophenotypes. In the broadest sense, any 
mature T-cell NHL is considered a peripheral T-cell lymphoma, with the exception of 
lymphoblastic lymphoma (ie, the lymphoma counterpart of T-cell acute lymphoblastic 
leukemia). Advances in the understanding of T-cell biology and molecular alterations 
of T-NHL over the past decade have led to a refinement of the World Health Organiza-
tion (WHO) classification system. Currently, the category PTCL comprises over 20 
  biologically and clinically distinct entities based on their epidemiology, clinical fea-
tures, morphology, immunophenotype, and underlying genetic lesions (Table 1).1,2
Worldwide, PTCLs represent approximately 12% of all NHLs.3 Ethnic and geo-
graphic variations account for differences in prevalence, however, with rates ranging 
from 24% in Asia to 4% in North America. The incidence in the USA increased 7.9% 
annually between 1992 and 2005.4 The reason behind the geographic variation is not 
entirely clear but may be related to exposure or genetic susceptibility to pathogenic agents 
in Asian countries, notably human T-cell lymphotropic virus type I (HTLV-1) infection 
and adult T-cell leukemia/lymphoma (ATLL) and Epstein–Barr virus (EBV) infection 
and NK/T-cell lymphoma (NKTCL).5 A recent international collaborative study6 also 
suggests geographic variation for other PTCL subtypes (Table 2). The International 
T-cell Lymphoma Project (ITLP) is an impressive effort involving over 22 centers 
worldwide that has collected data on 1314 cases of PTCL over 12 years.6 Overall, the 
most common PTCL subtypes identified were peripheral T-cell lymphoma, not otherwise Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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specified (PTCL-NOS) (25.9%), angioimmunoblastic T-cell 
lymphoma (AITL) (18.5%), natural killer/T-cell lymphoma 
NKTCL (10.4%), and adult T-cell leukemia/lymphoma 
(ATLL) (9.6%).6 With few exceptions, the course of most 
PTCL subtypes is aggressive and the clinical outcome is 
poor. The 5-year overall survival (OS) for the most com-
mon subtypes identified was 32%, 32%, 42%, and 14%, 
respectively.6
The optimal therapeutic strategy for most PTCL subtypes 
is unknown. A low overall incidence and prevalence of PTCLs 
combined with disease heterogeneity has made it challenging 
to conduct randomized or multi-institutional trials. Regimens 
for aggressive B-cell NHL are frequently used and, with the 
exception of anaplastic lymphoma kinase (ALK)-positive 
anaplastic large-cell lymphoma (ALCL) (which has an 
excellent outcome with anthracycline-based combination 
chemotherapy), other PTCLs have poor   outcomes.6 The 
tendency for poor survival in PTCL suggests that the same 
regimens may not be equally efficacious in patients with 
aggressive B- and T-cell lymphomas. New combinations 
Table 1 Mature T- and NK-cell neoplasms: the World Health Organization (WHO) classification 2001 and 20081,2
WHO classification 2001 WHO classification 2008
Leukemic T-PLL
T-LGLL
Aggressive NK-cell leukemia
ATLL (HTLv-1+)
T-PLL
T-LGL
Chronic LPDs of NK-cellsb
Aggressive NK-cell leukemia
ATLL (HTLv-1+)
Systemic eBv-positive T-cell LPDs of childhoodb
Nodal AiTL
ALCL, systemic type
PTCL-U
AiTL
ALCL, ALK-positive
ALCL, ALK-negativec
PTCL-NOS
extranodal extranodal NK-/T-cell lymphoma, nasal type
enteropathy-type T-cell lymphoma
Hepatosplenic γδ T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
extranodal NK-/T-cell lymphoma, nasal type
enteropathy-associated T-cell lymphoma
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Cutaneous Mycosis fungoides
Sézary syndrome
Primary cutaneous CD30+ T-cell LPD 
• ALCL, cutaneous type
• Lymphomatoid papulosisa
Borderline lesions
Mycosis fungoides
Sézary syndrome
Primary cutaneous CD30+ T-cell LPD
•   Primary cutaneous aggressive epidermotropic  
CD8+ TCLc
• Primary cutaneous small/medium CD4+ TCLc
Primary cutaneous γδ TCLb
Uncertain Blastic NK-cell lymphoma
Notes: aNot considered a neoplastic disorder; bnew distinct entity; cprovisional entity.
Abbreviations: T-PLL, T-cell prolymphocytic leukemia; T-LGLL, T-cell large granular lymphocytic leukemia; T-LGL, T-cell large granular lymphocytic leukemia; ATLL, adult 
T-cell leukemia/lymphoma; HTLv-1, human T lymphotropic virus, type i; LPD, lymphoproliferative disorder; PTCL, peripheral T-cell lymphoma; PTCL-U, peripheral T-cell 
lymphoma, unspecified; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase.
Table 2 Major lymphoma subtypes by geographic region in the international T-cell lymphoma project6
PTCL subtype Overall (%) North America (%) Europe (%) Asia (%)
PTCL-NOS 25.9 34.4 34.3 22.4
AiTL 18.5 16.0 28.7 17.9
ALCL, ALK+ 6.6 16.0 6.4 3.2
ALCL, ALK- 5.5 7.8 9.4 2.6
NKTCL 10.4 5.1 4.3 22.4
ATLL 9.6 2.0 1.0 25
enteropathy-type TCL 4.7 5.8 9.1 1.9
Hepatosplenic TCL 1.4 3.0 2.3 0.2
Primary Cutaneous ALCL 1.7 5.4 0.8 0.7
SCPTCL 0.9 1.3 0.5 1.3
Abbreviations: PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; ALK, 
anaplastic kinase; NKTCL, natural killer T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; TCL, T-cell lymphoma; SCPTCL, subcutaneous panniculitis-like T-cell 
lymphoma+; PTCL, peripheral T-cell lymphoma.
Note: Adapted from vose J, Armitage J, weisenburger D. international T-Cell Lymphoma Project. international peripheral T-cell and natural killer/T-cell lymphoma 
study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights 
reserved.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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of therapy, dose-intensified therapies and novel agents are 
necessary. This review summarizes the main clinicopathologic 
features of the common PTCL subtypes and the current and 
emerging treatment options that are available. Some subtypes 
have unique pathophysiology that require treatment modifica-
tions and this will also be reviewed where applicable.
PTCL-NOS
PTCL-NOS is the most common subtype of PTCL, account-
ing for approximately 26% of cases worldwide.6 This 
“default” PTCL category includes all cases not readily 
classifiable into other specific T-cell entities of the WHO 
classification. Distinguishing PTCL-NOS from ALK-
negative ALCL is challenging and the clinical relevance of 
distinguishing between these entities has been debated.7,8 
Distinct, as well as shared, chromosomal alterations have 
been described between PTCL-NOS and ALK-negative 
ALCL, the latter including gains at chromosomes 1q and 
3p and losses at chromosome 6q.9 Abnormalities at some 
of these loci have also been confirmed by higher resolution 
genomic analysis.10 Alterations of the NF kappa B signaling 
pathway have been described in a subset of PTCL-NOS, 
and expression of platelet-derived growth factor receptor 
alpha has also been reported in some cases.11,12 Streubel et al 
documented a recurrent translocation t(5:9)(q33:32) leading 
to the fusion of the inducible T-cell kinase gene located on 
chromosome 5 with the spleen tyrosine kinase gene located 
on chromosome 9 in ,20% of PTCL-NOS.13 These and other 
abnormalities suggest a role for alterations in constitutive 
activation of T-cell receptor signaling in disease pathogenesis 
and may pave the way for development of better diagnostic 
and prognostic markers.14
PTCL-NOS typically occurs in adults at the median 
age of 55–60 years, and a higher prevalence is seen in 
males.4,15 Patients frequently present with advanced disease 
and extranodal involvement is common despite previous 
classification as a “nodal” disease subtype.4,15 A prognostic 
index for T-cell lymphoma has been proposed, which 
incorporates the following factors: advanced age, poor 
performance status, elevated lactate dehydrogenase levels, and 
bone marrow involvement.16 In this model, 5-year OS ranged 
from 18% (with four factors) to 62% (with one factor).16 The 
treatment of PTCL-NOS is not well established and will be 
discussed further in this paper.
AITL
AITL, originally described as “angioimmunoblastic lymph-
adenopathy (AILD) with dysproteinemia,” is the second 
most common PTCL subtype, accounting for about 18.5% 
of cases.6 It is thought to derive from a T-follicular helper cell, 
based on phenotypic and gene expression profile analysis.17 
Most patients present in the sixth or seventh decade (median 
age 59–64 years) without any gender predilection.17 Originally 
thought to be a form of abnormal immune response, patients 
typically present with B-symptoms (fever, night sweats, 
unintentional weight loss), generalized lymphadenopathy, and 
advanced stage disease that may mimic an infectious process.17 
Laboratory studies commonly reveal anemia, hypergamma-
globulinemia, and an elevated lactate dehydrogenase, and a 
significant proportion of patients have circulating autoanti-
bodies, which may manifest as a positive direct antiglobulin 
test, cold agglutinins, cryoglobulins, and circulating immune 
complexes.15,17 A number of autoimmune phenomena have 
been reported in association with AITL.15,17 The course of 
AITL is variable, with occasional spontaneous remissions in 
some but, overall, prognosis is poor.
The pathogenesis of AITL is poorly understood.   Classical 
cytogenetic studies have identified a few recurrent chromo-
somal alterations in AITL, which include gains of chromo-
somes 3q, 5q, and 21, although the genes affected by these 
alterations are not known.9 High-resolution genomic analysis 
and whole genome or exome sequencing of these lymphomas 
might be more informative. Recent gene expression profile 
analysis of AITL has suggested a role of the tumor microen-
vironment in AITL pathogenesis.18 Underlying immune 
dysfunction has long been suspected, as has a role for viral 
infection, especially EBV and human herpesvirus 6, although 
specific viral factors or mediators influencing the course of 
disease are yet unknown.17
The best treatment approach for AITL is unknown and 
therapeutic strategies have ranged from assuming a “watch 
and wait” attitude to the use of single-agent steroids, 
cytotoxic drugs, or combination chemotherapy regimens. 
The use of steroids has been recommended in the elderly. 
However, when used as first-line therapy, the duration of 
response is shorter than with chemotherapy and, overall, 
combination chemotherapy appears to be superior to ste-
roids alone.19   Combination regimens, including CHOP 
  (cyclophosphamide, doxorubicin, vincristine, prednisone), 
CVP   (cyclophosphamide, vincristine, prednisone), and 
VAP (vincristine, doxorubicin, and prednisolone), can 
produce complete remission rates of up to 50%, but relapse 
rates remain high.19 At this time, no therapy has increased 
the long-term survival rate to more than 30%.6 Other 
therapeutic approaches in AITL have targeted immune 
dysregulation; these include cyclosporine, low-dose 
methotrexate, interferon-alpha, thalidomide, rituximab, and 
alemtuzumab, but there is no consensus on whether any Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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of these agents improve outcomes more than conventional 
therapy.19,20–24
Consolidation with high-dose therapy followed by 
autologous stem cell transplantation (ASCT) for patients in 
their first complete response (CR) or with chemosensitive 
relapse should be considered in suitable patients with AITL. 
The European Group for Blood and Marrow Transplantation 
retrospectively assessed 142 patients who received ASCT in 
differing situations (relapse, refractory, first CR) and, after a 
median follow-up of 31 months, OS was 67% at 24 months 
and 59% at 48 months. The estimated 4-year progression-
free survival (PFS) rate was best for patients receiving their 
transplant in CR (56% versus 30% in chemosensitive relapse 
and 23% in refractory disease).25 In young patients (median 
age 48), retrospective data on allogeneic transplantation are 
encouraging but patient cohorts are limited.26
ALCL
ALCL was originally described in 1985 by Stein et al as 
a lymphoma composed of large anaplastic lymphocytes 
that express CD30.27 Since then, there has been significant 
progress in further classifying ALCL based on the pres-
ence of the characteristic chromosomal translocation t(2;5)
(p23;q35), which results in the nucleophosmin (NPM)/ALK 
(NPM-ALK) fusion protein and causes constitutive activa-
tion of the ALK tyrosine kinase, leading to uncontrolled cell 
proliferation.28 An understanding of alterations in different 
signaling pathways affected by the translocation, especially 
the Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT) (JAK-STAT) pathway that leads to 
constitutive activation of STAT3, the phosphatidylinosi-
tol 3-kinase (PI3-kinase)/protein kinase (AKT) pathway, 
CD30, Myc, phospholipase C-γ (PLCγ), and growth factor 
receptor–bound protein 2 (Grb2) (an adaptor protein) have 
been described.29 Translocations involving ALK and other 
partner genes have also been documented, but they only 
account for a minority of cases.29
NPM-ALK translocations are seen in 60%–85% of sys-
temic ALCL with higher frequencies seen in the pediatric 
and young-adult age groups.28,30,31 Because of its unique 
clinicopathologic features, ALK-positive ALCL is con-
sidered a distinct entity, distinguished from ALK-negative 
ALCL in the WHO classification.1 ALK-positive patients 
have a median age of 34 years compared with a median age 
of 58 years for patients with ALK-negative ALCL, with no 
differences in gender or stage at presentation.31
ALK-positive ALCL is a chemosensitive malignancy 
with outcomes comparable to, or better than,   International 
  Prognostic Index (IPI)–adjusted diffuse large B-cell 
  lymphoma (DLBCL) following anthracycline-based combi-
nation chemotherapy.32 Trials reporting solely ALK-positive 
ALCL are few, but in one series, a CR rate of 77% was 
reported with OS of 71% at 10 years.33 Due to superior 
outcomes of adult ALK-positive ALCL with anthracycline-
based chemotherapy, transplant should only be considered 
at relapse. ALK-positive ALCL patients undergoing ASCT 
at relapse have a 67%–100% 3-year PFS and a 78%–100% 
3-year OS.34,35 Prognosis for ALK-negative ALCL lies 
between ALK-positive ALCL and PTCL-NOS with a 5-year 
OS of 49% compared with 19% for PTCL-NOS.6
The fact that NPM-ALK plays a critical role in the 
development and pathogenesis of ALK+ ALCL has made 
this chimeric protein a therapeutic target in this disease. 
Crizotinib, an inhibitor of the ALK tyrosine kinase, is 
active in non-small-cell lung cancers expressing ALK.36 
Two case reports indicate sensitivity of relapsed, advanced 
ALK-positive ALCLs to ALK inhibition.37 Immunotherapy 
targeting CD30 is another possible approach and will be 
discussed further.
NKTCL
NK cells are closely related to T cells and neoplasms derived 
from these cells are thus classified within the same group. 
Overall, NKTCLs represent 10.4% of all PTCL, however 
prevalence is much higher in Asian countries (22.4%) com-
pared with North America and Europe (4%–5%) (Table 2).6 
NKTCL is associated with EBV and usually presents in men 
at the median age of 43.38 Though most cases present in the 
nasal region and associated structures, identical tumors can 
also occur in extranasal sites, such as the skin, soft tissue, 
gastrointestinal tract, and testis. Extranasal cases have more 
adverse clinical features and poorer survival, even with 
apparently localized disease (5-year OS, 9% versus 42%).6 
As with other T-cell lymphomas, the pathogenesis of NKTCL 
remains poorly understood. A recurrent genetic alteration of 
chromosome 6q has been described and a potential tumor 
suppressor HACE1 has recently been mapped to this location, 
but the role of this gene in disease pathogenesis is currently 
not known.39
Therapy for NKTCL is not standardized; however, radio-
therapy is an effective treatment for patients with limited 
disease. In a study of 64 patients with early stage NKTCL 
who received radiotherapy alone or chemoradiotherapy as 
first-line therapy, there was no difference in 5-year OS (57% 
versus 62%, P = 0.47).40 For patients with disseminated or 
relapsing disease, a Phase II study of L-asparaginase with Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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methotrexate and dexamethasone revealed a 61% CR rate 
and the main toxicities were hepatitis, cytopenias, and 
allergy.41
ATLL
ATLL is caused by the retrovirus human T-lymphotropic 
virus type I (HTLV-1), which is endemic in Japan, Central 
Africa, the Caribbean, Papua New Guinea, South America, 
and is present in regions of the USA where populations have 
immigrated. HTLV-1 affects 20 million individuals worldwide 
although 95% will likely remain asymptomatic carriers. The 
estimated lifetime risk of developing ATLL is 2%–6% among 
HTLV-1 carriers.42 ATLL is subdivided into four clinical 
subtypes: (1) acute (leukemic) (57%), (2) lymphoma (19%), 
(3) chronic (19%), and (4) smoldering (5%).43 The main 
clinical manifestations of ATLL include lymphadenopathy, 
hepatosplenomegaly, skin lesions, osteolytic lesions, and 
hypercalcemia depending on the subtype. Prognoses for the 
acute and lymphoma subtypes are the poorest with a median 
survival of only 6.2 and 10.2 months, respectively.43
Disease pathogenesis involves interactions between viral 
and host factors. A variety of viral proteins with transforming 
activity have been described, but most work has focused on 
the Tax protein, which is thought to activate the NF kappa 
B transcription factor complex.44 Recent work has suggested 
that c-Rel and IRF-4 expression is associated with antiviral 
resistance of ATLL.45 Array-based comparative genomic 
hybridization studies have also highlighted differences in 
chromosomal alterations between the acute and lymphoma 
subtypes and have provided limited information regarding 
the genes targeted by these alterations.46 Understanding 
molecular pathways affected by the viral factors and tumor-
associated genetic abnormalities might allow for targeted 
and effective therapeutic approaches.
Chemotherapy has had limited success in treatment of 
ATLL. The Japan Clinical Oncology Group has performed 
six prospective clinical trials of conventional chemotherapy.47 
Most recently, the results of a Phase III study suggest that, at 
the expense of higher toxicities, the vincristine, cyclophos-
phamide, doxorubicin, and prednisone (VCAP); doxorubicin, 
ranimustine, and prednisone (AMP); and vindesine, etoposide, 
carboplatin, and prednisone (VECP) regimens are superior 
to biweekly CHOP in newly diagnosed, acute, lymphoma, 
or unfavorable chronic types of ATLL. The rate of CR was 
higher in the VCAP-AMP-VECP arm than the biweekly 
CHOP arm (40% versus 25%, P = 0.020). OS at 3 years was 
24% in the VCAP-AMP-VECP arm and 13% in the CHOP 
arm (P = 0.085).48
Several studies have shown promising use of zidovudine 
(AZT) and interferon alpha (IFN-α). Combination of AZT and 
IFN-α in acute leukemia or lymphomatous forms of ATLL 
have produced CR rates ranging from 26%–58%, median 
OS ranging from 3–18 months, and median OS for respond-
ers ranging from 13–28 months.49–51 A recent meta-analysis 
reported a 5-year OS rate of 46% for patients receiving first-
line antiviral treatment and concluded that AZT and IFN-α 
should be the standard first-line therapy of leukemic subtypes 
of ATLL.52 Monoclonal antibodies (anti-CD25, anti-CD4, 
anti-CD52, anti-CCR4, antitransferrin receptor) and novel 
agents (arsenic trioxide, bortezomib) have been tested in small 
numbers of patients and clinical trials are needed to better 
define the roles of these agents.47 There is little long-term 
benefit to autologous stem cell transplantation, although pro-
longed disease-free survival has been reported for allogeneic 
transplant in retrospective analyses.53,54
Rare peripheral T -cell lymphoma  
subtypes
Enteropathy associated T-cell lymphoma (EATL) accounts 
for less than 5% of PTCL and has been recognized as having a 
poor prognosis.6 The disease is usually associated with celiac 
disease and the HLA DQ2 haplotype, and is more commonly 
seen in Northern Europe due to a higher incidence of celiac 
disease.6,55 Typically, patients are older men who present 
with diarrhea and abdominal pain. Like other subtypes of 
PTCL, the outcome of patients with this disease receiving 
anthracycline-based chemotherapy has been poor, with 
most patients relapsing or dying of their disease.   Treatment 
is complicated by poor nutrition and a significant risk of 
bowel perforation.55 Small series of individuals undergo-
ing regimens involving ASCT have shown some benefit.56 
Cladribine therapy has recently been proposed for treating 
refractory celiac disease type II, which is considered a pre-
cursor of EATL, with good histologic and clinical response, 
though long-term studies are warranted.57
Hepatosplenic T-cell lymphoma is another uncommon 
T-cell lymphoma mainly seen in young males with a median 
age of 35 years. The disease may be seen following organ 
transplantation or be related to other causes of immunosup-
pression and is slightly more common in North America and 
Europe than Asia.6,58
Subcutaneous panniculitis-like T-cell lymphoma is one 
of the rarest subtypes of T-cell lymphoma that does not 
appear to have any geographic variation.6 It can be seen 
in any age, but the median age is 36 years, with a male to 
female ratio of 2:1.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Optimal therapies for the aforementioned entities remain 
undefined at the time of writing.
Emerging treatment options for 
PTCL
Until the rituximab era, treatment for patients with PTCL 
was approached in the same way as that for B-cell NHL. 
Outside of a clinical trial, CHOP or CHOP-like chemotherapy 
regimens (eg, EPOCH [etoposide, prednisone, vincristine, 
cyclophosphamide, doxorubicin] or hyperCVAD [hyper-
fractionated cyclophosphamide, vincristine, doxorubicin 
and decadron] alternating with high-dose methotrexate and 
cytarabine) are considered reasonable options.59 The large 
Intergroup trial, which established that CHOP was equally 
efficacious and less toxic than other chemotherapy combi-
nations in aggressive NHLs, was conducted in an era when 
routine immunophenotyping to distinguish B- and T-cell 
lineage was not performed.60 Unfortunately, with the notable 
exception of ALK-positive ALCL, outcomes with CHOP in 
PTCL have been poor.6 But, despite these suboptimal results, 
few studies have compared CHOP with other regimens 
in the initial treatment of PTCL. Furthermore, the role of 
anthracyclines, particularly in the treatment of PTCL-NOS, 
has been questioned.6
The German High-Grade Non-Hodgkin’s Lymphoma 
Group evaluated the outcome of 289 patients with ALK-
positive ALCL, ALK-negative ALCL, PTCL-unclassified 
(now PTCL-NOS), and AITL treated on their protocols.61 
Treatment consisted of 6–8 cycles of CHOP or etoposide plus 
CHOP (CHOEP). Three-year event-free survival (EFS) and 
OS was 75.8% and 89.8% (ALK-positive ALCL), 50.0% and 
67.5% (AITL), 45.7% and 62.1% (ALK-negative ALCL), 
and 41.1% and 53.9% (PTCL-U). For younger patients, the 
addition of etoposide improved response rates. The differ-
ence in EFS for younger patients and ALK-positive ALCL 
treated with CHOP or CHOEP was impressive (3-year EFS 
for CHOEP patients was 91.2% versus 57.1% for patients 
treated with CHOP, P = 0.12), and no statistically significant 
difference was seen in the remaining patients when ALK-
positive ALCL was excluded (3-year EFS for CHOEP 
patients 60.7% versus 48.3% for patients treated with CHOP, 
P = 0.57). Although this difference was not statistically 
significant, the authors concluded that CHOEP should be 
administered as first-line therapy to younger patients with 
T-cell lymphoma.
The Groupe Ouest-Est D’etudes Des Leucémies Aigües 
Et Autres Maladies Du Sang (GOELAMS) tested alternating 
VIP   (etoposide, ifosfamide, cisplatin)/ABVD (adriamycin, 
bleomycin, vinblastine, dacarbazine) for a total of six cycles 
against CHOP for eight cycles in treatment-naïve patients 
with PTCLs and found there was no difference in EFS and 
OS between these regimens.62 A Korean group evaluated a 
CHOP-like regimen (CEOP-B [cyclophostamide, epirubi-
cin, vincristine, prednisone, bleomycin]), with epirubicin 
substituted for doxorubicin and the addition of bleomycin, 
in patients with T-cell lymphomas (one patient with lym-
phoblastic lymphoma) with primarily low-risk disease (38% 
IPI 0 or 1) and reported a 5-year OS of 49%; however, the 
estimated 5-year PFS was only 30%.63 Table 3 highlights 
other frontline therapeutic studies. However, none of these 
report outcomes that are statistically significantly improved 
over CHOP at this time.62–68
Stem cell transplantation
Poor results with conventional chemotherapy have led 
to the exploration of high-dose chemotherapy supported 
by autologous or allogeneic stem cell transplantation. 
A number of uncontrolled prospective and retrospective 
studies suggest that upfront high-dose chemotherapy with 
ASCT as consolidation in patients who attain CR follow-
ing first-line therapy may result in superior disease control 
and improved OS.69 In a retrospective study of 115 patients 
with PTCL, the Grupo Español de Linfomas y Trasplantes 
de Médula Ósea (GEL-TAMO) showed a 5-year OS rate of 
80% was achieved in 37 patients who were transplanted in 
first CR compared with 45% in those treated in a salvage 
  setting.70 Reimer et al conducted the largest prospective 
study of upfront ASCT for patients with PTCL.71 Of 83 
patients enrolled, 55 underwent ASCT; the estimated 3-year 
OS rate for these patients ASCT was 71% compared with 
11% for those that did not. About 33% of patients did not 
undergo ASCT for a variety of reasons, including disease 
progression (in 29%).71
The role of allogeneic transplantation has also been 
  preliminarily investigated. In a prospective study of 
17 patients with relapsed or refractory PTCL undergoing 
salvage chemotherapy and reduced-intensity allogeneic 
transplantation, at a median follow-up of 28 months, 14/17 
patients were alive. The estimated 3-year OS and PFS were 
81% and 64%, respectively, suggesting a possible graft-
versus-lymphoma effect.72 The therapy-related mortality 
was 6%. In a retrospective study of 77 patients with PTCL 
who underwent allogeneic stem cell transplantation, the 
5-year OS and EFS rates were 57% and 53%, respectively.73 
The 5-year OS for chemoresistant patients was 29% and 
the treatment-related mortality was 33%. The German Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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High-Grade Non-Hodgkin’s Lymphoma Study Group is 
initiating a randomized multicenter trial comparing upfront 
ASCT with allogeneic stem cell transplantation.
Novel agents
A significant effort has been made to identify novel targets 
for the treatment of PTCL and a number of targeted therapies 
are being investigated in early clinical trials (Tables 3 and 4). 
These agents include antimetabolites, histone deacetylase 
(HDAC) inhibitors, and immunotherapies, as well as others.
Antimetabolites
Pralatrexate (PDX) is an antifolate agent and one of two 
drugs approved by the US Food and Drug Administration 
(FDA) for use in relapsed or refractory PTCL. PDX is 
structurally similar to methotrexate but has a greater affinity 
for the reduced folate carrier and exerts its effects by bind-
ing to and activating the enzyme dyhydrofolate reductase, 
thus depleting intracellular stores of reduced folate and 
interfering with DNA synthesis.74 PROPEL (Pralatrexate in 
Relapsed and Refractory Peripheral T-cell Lymphoma) is a 
prospective single-arm multicenter study in patients with 
relapsed or refractory aggressive PTCL.75 The study enrolled 
115 patients with a variety of PTCL subtypes between August 
2006 and April 2008, out of which 109 were evaluable. The 
treatment schedule consisted of PDX given at 30 mg/m2 
intravenously weekly for 6 weeks followed by 1-week’s rest in 
a 7-week cycle. Folic acid and vitamin B12 supplementation 
was administered for all patients. Based on an independent 
central review, the overall response rate (ORR) for all 
patients was 29%, with 9 patients (9%) achieving a complete 
remission. Sixty-six percent of the responses occurred after 
cycle 1 of therapy and the median duration of response was 
9.4 months. Mucositis was seen in over 70% of patients, and 
was grade 3 or 4 in 21%. Hematologic toxicity consisted of 
thrombocytopenia and anemia. Other toxicities were mild and 
included fatigue, nausea, dyspnea, and mild abnormalities 
of liver function and serum electrolytes.
Other notable antimetabolites that have been studied in 
PTCL include gemcitabine, clofarabine, nelarabine, and 
forodesine. Zinzani et al used gemcitabine in 39 patients 
with mycoses fungoides and PTCL and achieved an overall 
response rate of 51%.76 Horwitz et al presented preliminary 
data on clofarabine at a starting dose of 4 mg/m2 daily for 3 
Table 3 Selected studies of first-line therapies in PTCL
Study Agent Patient number (n) ORR Notable toxicities
Kim64 CHOeP + gemcitabine 26 77% Grade 4 neutropenia (54%)
Sung63 CeOP-B 52 63.5% Neutropenia
Gallamini66 Alemtuzumab + CHOP 24 75% Grade 4 neutropenia and CMv reactivation
Other major infections-JCv, pulmonary  
invasive aspergillosis, staph  
sepsis and pneumonia
Kim65 Alemtuzumab + CHOP 20 80% 90% grade 4 neutropenia
55% febrile neutropenia
25% CMv reactivation*
Simon62 viP-rABvD vs CHOP 21 88 patients  
randomized
62%, no difference  
between two arms
Hematologic toxicity, transfusion requirement, 
and hospitalizations higher in viP-rABvD arm
Takamatsu67 THP-COP 53 66% Grade 3/4 cytopenias
Kluin-Nelemans68 Alemtuzumab + CHOP  
(intensified)
20 90% Neutropenic fever, CMv reactivation/disease,  
eBv-related lymphoma
Note: *Study closed due to adverse events.
Abbreviations:  ORR,  overall  response  rate;  CHOP,  cyclophosphamide,  doxorubicin,  vincristine,  prednisone;  CHOeP,  cyclophosphamide,  doxorubicin,  vincristine, 
prednisone, etoposide; CEOP-B, modified cyclophosphamide, epirubicin, vincristine, prednisone; VIP-rABVD, alternative therapeutic schedule including etoposide, ifosfamide, 
cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine; THP-COP, pirarubicin, cyclophosphamide, vincristine, prednisolone; CMv, cytomegalovirus;   
JC, John Cunningham virus; eBv, epstein–Barr virus; PTCL, peripheral T-cell lymphoma.
Table  4  Selected  studies  of  novel  therapies  in  relapsed  or 
refractory PTCL
Study Agent Patients (n) ORR
Mercieca92 Pentostatin 145 34%
Sallah93 Gemcitabine 10 60%
enblad83 Alemtuzumab 14 35%
Arkenau94 Gemcitabine combination 16 69%
Dang86 Denileukin diftitox 27 48%
Bartlett84 Anti-CD30, iratumumab 24 17%
Kim95 Alemtuzumab + DHAP 24 50%
Zinzani76 Gemcitabine 20 55%
D’Amore87 Anti-CD4, zanolimumab 21 24%
Dueck90 Lenalidomide 24 30%
O’Connor74 Pralatrexate 115 29%
Piekarz81 Romidepsin 47 38%
Coiffier96 Romidepsin 131 30%
Abbreviations:  DHAP,  dexamethasone-cytarabine-cisplatin;  PTCL,  peripheral 
T-cell lymphoma.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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consecutive days repeated every 3 weeks. Of the first eleven 
patients, there was only one PR and one CR lasting more 
than 9 months.77 Nelarabine is effective in T-ALL, however, 
its activity in PTCL is limited and associated with excessive 
neurotoxicity.78,79 Forodesine has demonstrated activity in 
T-ALL and cutaneous T-cell lymphoma [CTCL] and further 
studies in PTCL are needed.80
HDAC inhibitors
HDAC inhibitors are epigenetic agents with early clinical 
activity in PTCL. Two agents of this class, vorinostat and 
romidepsin, are currently approved for the treatment of 
CTCL in the USA. HDAC inhibitors are thought to exert 
their antitumor effect by modulating gene expression and 
thereby influencing cell differentiation or apoptosis. In a 
Phase II study of 47 patients with relapsed or refractory PTCL, 
romidepsin showed an ORR of 38% and the median duration 
of response was 8.9 months.81 The dose was 14 mg/m2 given 
on days 1, 8, and 15 of a 28-day cycle. Common toxicities 
were nausea, fatigue, and transient thrombocytopenia and 
granulocytopenia. Romidepsin was FDA approved for the 
treatment of relapsed or refractory PTCL in June 2011.
immunotherapy
Alemtuzumab is a humanized monoclonal antibody against 
CD52, which is highly expressed on malignant T cells.82 
Enblad et al studied alemtuzumab in 14 patients with 
advanced-stage PTCL. The ORR was 36%, including three 
complete remissions lasting 2, 6, and 12 months, but there 
was significant myelotoxicity and opportunistic infection.83 
Alemtuzumab has also been studied in combination with 
CHOP as the initial treatment of PTCL. Despite high CR 
rates, the upfront studies documented serious infectious 
complications.65,66
CD30, a member of the tumor necrosis factor receptor 
family, is expressed on malignant hematopoietic cells and 
plays a role in regulation of cell growth and survival. Anti-
CD30 monoclonal antibodies are of potential interest in PTCL 
that expresses CD30, notably ALCL. Bartlett et al reported a 
Phase I multidose study of the chimeric SGN-30 monoclonal 
antibody in 24 patients with relapsed and refractory 
Hodgkin’s lymphoma and CD30+ ALCL.84 Treatment 
was well tolerated and, although there were no responses 
in Hodgkin’s lymphoma, the PR rate was 17% in ALCL. 
SGN-35 is a drug–antibody conjugate in which SGN-30 is 
linked to auristatin. In a Phase I trial including 36 patients 
with Hodgkin’s lymphoma and three with other CD30+NHL, 
no dose-limiting toxicity was identified. The ORR for patients 
treated at a dose of at least 1.2 mg/kg was 45%, including 
five (23%) CRs.85
Denileukin diftitox is a recombinant fusion protein 
containing the interleukin 2 (IL-2) protein and a truncated 
portion of the diphtheria toxin, which targets cells expressing 
the IL-2 receptor. It is approved for the treatment of CTCL 
and also appears to have activity against PTCL. Dang et al 
reported on 27 patients with relapsed or refractory PTCL. 
Six patients (22%) achieved a CR and seven (26%) showed 
a PR. The median PFS was 6 months after a median of 2.5 
prior therapies.86
Other antibodies being studied in PTCL include zanoli-
mumab, directed at CD4+ cells, and siplizumab, directed at 
CD2+ cells.87,88
Other investigational therapies
Lenalidomide is an immunomodulatory agent that has 
demonstrated clinical efficacy in several hematologic malig-
nancies. Its exact mechanism of action is unknown but is 
hypothesized to include direct cytotoxicity to tumor cells, 
immunomodulatory responses such as cytokine modulation, 
enhanced NK- and T-cell function, and anti-angiogenesis 
effects.89 Dueck et al have reported the interim analysis 
of a Phase II study of 24 patients with PTCL.90 The over-
all response rate was 7/23 (30%) evaluable patients. All 
were partial responses and two patients had stable disease 
for $5 cycles. The most common grade-4 adverse event 
was thrombocytopenia (33%) and the most common grade-3 
adverse events were neutropenia (21%), febrile neutropenia 
(17%), and pain not otherwise specified (17%).
Bortezomib, the first proteasome inhibitor to enter   clinical 
trials, was initially approved by the FDA for the treatment 
of relapsed and refractory multiple myeloma. Clinical   trials 
are exploring the activity of bortezomib in PTCL. Lee 
et al conducted a Phase I trial of CHOP and bortezomib in 
13 previously untreated patients with PTCL or NK/T-NHL.91 
Although they did not meet the maximum tolerated dose of 
bortezomib at 1.6 mg/m2 on a weekly schedule, the CR was 
61.5%. They concluded that the regimen was well tolerated 
and active.
Conclusion
The treatment of patients with PTCL remains challenging. 
The rarity of PTCL and lack of randomized trials are the 
principal reasons for a lack of consensus regarding optimal 
therapy for T- and NK-cell neoplasms. Current recom-
mendations are based on small case series, Phase II trials, 
and expert opinions. In the frontline setting, there is no Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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accepted standard and CHOP or CHOP-like chemotherapy 
is frequently used. The addition of etoposide to CHOP in 
younger patients appears to improve response rates. ASCT 
can improve long-term disease control and should be applied 
either during the first CR/PR, or as part of upfront treatment 
for most PTCL subtypes, excluding ALK-positive ALCL. 
The role of allogeneic stem cell transplantation is still under 
investigation. Unfortunately, most patients relapse after 
initial induction chemotherapy and new and more effective 
agents are desperately needed. In the relapsed, refractory 
setting, pralatrexate, a folate analog, and romidepsin, a his-
tone deacetylase inhibitor, are the only FDA-approved thera-
pies for second-line therapy in PTCL. A number of other 
novel agents show preliminary activity and a large develop-
ment pipeline exists. Patients should be entered on clinical 
trials whenever possible. To date, treatment approaches have 
been similar among the PTCL subtypes; however, given the 
underlying biologic heterogeneity, subtype-specific therapies 
may be more optimal. This approach has been utilized in the 
treatment of NKTCL and ATLL, where radiotherapy and 
AZT/IFN should be considered, respectively.
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